Bio-Rad Makes Progress Recovering from Recent Ransomware Attack
December 13 2019 - 4:52PM
Business Wire
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) a global leader
of life science research and clinical diagnostic products, today
announced that the Company is making good progress recovering from
a ransomware attack that was detected on Bio-Rad’s network on
December 5, 2019. Once the malicious software was detected, Bio-Rad
immediately took certain systems offline as part of its
comprehensive response to contain the activity.
The Bio-Rad website and telephone communications have been
brought back online. Bio-Rad is continuing to restore affected
systems and return to normal operations and the Company has resumed
taking orders and shipping product. Our global ERP system was not
affected by the attack, and we have found no evidence of
unauthorized access, transfer, or misuse of data or personal
information.
“We appreciate the patience and understanding of our customers
as we work to re-establish our systems following this attack,” said
Norman Schwartz, Bio-Rad President and Chief Executive Officer. “I
would like to recognize the incredible work of Bio-Rad employees
around the world this past week and commend their outstanding
efforts to minimize disruption to our customers as we navigated
this situation.”
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global
leader in developing, manufacturing, and marketing a broad range of
innovative products for the life science research and clinical
diagnostic markets. With a focus on quality and customer service
for over 65 years, our products advance the discovery process and
improve healthcare. Our customers are university and research
institutions, hospitals, public health and commercial laboratories,
biotechnology, pharmaceutical, as well as applied laboratories that
include food safety and environmental quality. Founded in 1952,
Bio-Rad is based in Hercules, California, and has a global network
of operations with more than 8,000 employees worldwide. Bio-Rad had
revenues exceeding $2.2 billion in 2018. For more information,
please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding the recent
ransomware attack. Forward-looking statements generally can be
identified by the use of forward-looking terminology such as,
“continue,” “expect,” “anticipate,” “may,” “will,” “intend,”
“estimate,” “believe,” or similar expressions or the negative of
those terms or expressions, although not all forward-looking
statements contain these words. Such statements are based on
current expectations and assumptions of the company and involve
risks and uncertainties, which could cause actual results to vary
materially from those expressed in or indicated by the
forward-looking statements. For further information regarding the
Company’s risks and uncertainties, please refer to the “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operation” in Bio-Rad’s public reports
filed with the Securities and Exchange Commission, including our
most recent Annual Report on Form 10-K and our Quarterly Reports on
Form 10-Q. Bio-Rad cautions you not to place undue reliance on
forward-looking statements, which reflect an analysis only and
speak only as of the date hereof. We disclaim any obligation to
update these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191213005492/en/
Bio-Rad Laboratories, Inc. Tina Cuccia, Corporate Communications
510-724-7000 tina_cuccia@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Apr 2023 to Apr 2024